Skip to main content
Fig. 7 | BMC Neurology

Fig. 7

From: Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma

Fig. 7

Differential putative chemotherapeutic and immunotherapeutic response. (A) The response of 38 immune checkpoints among the high- and low-risk sets in glioma. (B) Survival curve of PDCD1 (PD1) among high- and low-risk subtypes. (C) Survival curve of CTLA4 between high- and low-risk subtypes. (D-E) The TIDE value and response results to immunotherapy of patients with glioma. (F) The Submap algorithm showed that the high-risk set was more sensitive to CTAL-4 and anti-PD-1 therapy (Bonferroni-corrected P < 0.05). (G) Estimated IC50 shows the efficiency of chemotherapy to the high- and low-risk sets by cisplatin, erlotinib, dasatinib, lapatinib, and etoposide; ***P < 0.001

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us